Dela Cruz JS - Search Results

1

A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.

Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. Penichet ML, et al. Among authors: dela cruz js. Hum Antibodies. 2001;10(1):43-9. Hum Antibodies. 2001. PMID: 11455061

2

Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.

Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. Dela Cruz JS, et al. Mol Immunol. 2006 Feb;43(6):667-76. doi: 10.1016/j.molimm.2005.04.007. Mol Immunol. 2006. PMID: 15908002

3

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. Ng PP, et al. Among authors: dela cruz js. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10706-11. doi: 10.1073/pnas.162362999. Epub 2002 Jul 29. Proc Natl Acad Sci U S A. 2002. PMID: 12149472 Free PMC article.

4

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.

Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML. Dela Cruz JS, et al. Vaccine. 2003 Mar 28;21(13-14):1317-26. doi: 10.1016/s0264-410x(02)00741-7. Vaccine. 2003. PMID: 12615426

5

Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.

Dela Cruz JS, Morrison SL, Penichet ML. Dela Cruz JS, et al. Vaccine. 2005 Sep 15;23(39):4793-803. doi: 10.1016/j.vaccine.2005.04.041. Vaccine. 2005. PMID: 15967544

6

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.

Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML. Helguera G, et al. Among authors: dela cruz js. Vaccine. 2006 Jan 16;24(3):304-16. doi: 10.1016/j.vaccine.2005.07.073. Epub 2005 Aug 10. Vaccine. 2006. PMID: 16125282

7

Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.

Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Dela Cruz JS, et al. J Immunol. 2000 Nov 1;165(9):5112-21. doi: 10.4049/jimmunol.165.9.5112. J Immunol. 2000. PMID: 11046042

8

A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity.

Penichet ML, Dela Cruz JS, Challita-Eid PM, Rosenblatt JD, Morrison SL. Penichet ML, et al. Among authors: dela cruz js. Cancer Immunol Immunother. 2001 Feb;49(12):649-62. doi: 10.1007/s002620000155. Cancer Immunol Immunother. 2001. PMID: 11258791 Free PMC article.

9

Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).

Peng LS, Penichet ML, Dela Cruz JS, Sampogna SL, Morrison SL. Peng LS, et al. Among authors: dela cruz js. J Interferon Cytokine Res. 2001 Sep;21(9):709-20. doi: 10.1089/107999001753124444. J Interferon Cytokine Res. 2001. PMID: 11576465

10

Antibody-cytokine fusion proteins: innovative weapons in the war against cancer.

Dela Cruz JS, Huang TH, Penichet ML, Morrison SL. Dela Cruz JS, et al. Clin Exp Med. 2004 Oct;4(2):57-64. doi: 10.1007/s10238-004-0039-y. Clin Exp Med. 2004. PMID: 15672942 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters